Physician

Julian Llado Espiritu, M.D.

According to 2025 Medicare claims, Julian Espiritu, M.D. (NPI: 1730174970) practices nephrology in the Charleston, WV market, with the plurality of this provider's patient population coming from Kanawha, WV. This provider's primary affiliated billing organization is RENAL CONSULTANTS, PLLC (NPI: 1295720449; TIN: 550768008) and primary practice location at 25303-1478. Espiritu is affiliated with the ACO West Virginia (ACO ID: A3563) and Vandalia Health Network (ACO ID: A4513), participating under the MSSP model.

Espiritu's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 384 traditional Medicare patients, billed 230,588 HCPCS/CPT codes, and received $1,901,391 in Medicare payments. The top billing code was 36415 (Insertion of needle into vein for collection of blood sample). Part D data shows 7,093 prescription claims across 710 beneficiaries totaling $4,224,452 in drug costs, led by Jardiance (Empagliflozin). DME data shows 200 claims. Open Payments data shows 244 records totaling $32,232. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $586,212 to $1,901,391. Similarly, Part D prescription costs have moved sharply higher in recent years, from $702,597 to $4,224,452. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $18,362 to $751.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	719	267,816	$586,212
2016	903	426,243	$804,292
2017	841	483,511	$823,817
2018	813	529,792	$853,674
2019	792	613,076	$984,477
2020	627	465,120	$1,142,303
2021	557	386,327	$822,253
2022	556	364,870	$2,503,626
2023	507	310,103	$1,414,473
2024	384	230,588	$1,901,391

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	593	5,070	$702,597
2016	680	5,840	$830,774
2017	716	6,165	$855,486
2018	681	5,225	$700,278
2019	702	4,919	$1,066,241
2020	627	4,460	$1,286,727
2021	663	5,032	$2,079,663
2022	848	7,818	$5,008,477
2023	836	8,221	$5,043,855
2024	710	7,093	$4,224,452

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	66	255	$17,592
2016	61	207	$7,938
2017	N/R	112	$1,968
2018	N/R	44	$1,012
2019	N/R	83	$2,341
2020	N/R	68	$3,073
2021	N/R	64	$1,568
2022	N/R	93	$3,396
2023	N/R	216	$7,144
2024	N/R	200	$4,978

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
36415	Insertion of needle into vein for collection of blood sample	299	961	$9
85027	Complete blood cell count (red cells, white blood cell, platelets), automated test	294	816	$6
82043	Urine microalbumin (protein) level	283	623	$6
82570	Creatinine level to test for kidney function or muscle injury	291	632	$5
81003	Automated urinalysis test	294	656	$2

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jardiance	Empagliflozin	502	33,989	$643,348
Ozempic	Semaglutide	328	15,940	$512,932
Farxiga	Dapagliflozin Propanediol	376	25,594	$474,260
Keveyis	Dichlorphenamide	13	390	$441,956
Mounjaro	Tirzepatide	288	12,255	$437,716

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7503	Tacrolimus, extended release, (envarsus xr), oral, 0.25 mg	N	N/R	12	$1,362
J7518	Mycophenolic acid, oral, 180 mg	N	N/R	22	$1,151
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	59	$1,043
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	36	$589
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	40	$489

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	244	$32,232	Boehringer Ingelheim Pharmaceuticals, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Julian Llado Espiritu, M.D.?

Tedicare shows public-source Medicare data for Julian Llado Espiritu, M.D. (NPI 1730174970), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Julian Llado Espiritu, M.D. have ACO affiliation data?

Julian Llado Espiritu, M.D. is shown with ACO affiliation data for ACO West Virginia (MSSP, ACO ID A3563) and Vandalia Health Network (MSSP, ACO ID A4513).

What billing organization is linked to Julian Llado Espiritu, M.D.?

Julian Llado Espiritu, M.D. is linked to RENAL CONSULTANTS, PLLC (billing NPI 1295720449) in the available physician profile data.

Does Julian Llado Espiritu, M.D. have Open Payments data?

Julian Llado Espiritu, M.D. has 244 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.